The Conversation (0)
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of fiscal year 2026, which ended September 30, 2025.
The Company's full financial statements and related MD&A for the first quarter ended September 30, 2025, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Eric A. Adams, InMed Chief Executive Officer, commented, "Fiscal 2026 is shaping up to be another strong year for InMed as we advance our lead program INM-901 toward clinical readiness. INM-901 continues to demonstrate compelling data across multiple preclinical models, reinforcing its potential as a differentiated small-molecule therapy targeting Alzheimer's disease. With IND-enabling activities advancing, we are entering an important stage in translating INM-901's scientific promise into clinical evaluation."
Mr. Adams continued, "On the corporate front, the addition of two new directors further strengthens our Board's breadth of expertise and supports our continued growth and strategic execution. Additionally, the Company closed the quarter with approximately $9.3 million in cash allowing us to execute on program milestones into the fourth quarter of calendar year 2026."
Business Update - Pharmaceutical Development Programs
INM-901: Targeting multiple biological pathways associated with Alzheimer's disease
InMed's proprietary small-molecule drug candidate INM-901 continues to advance as a potential treatment for Alzheimer's disease through its multiple mechanisms of action targeting several biological pathways associated with disease progression. This quarter, management presented a scientific poster at the 2025 Alzheimer's Association International Conference (AAIC) entitled, "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study ".
This study measured hippocampal RNA expression, inflammatory markers, immunohistochemistry and behavioral differences using a 7-month treatment duration in subjects with more advanced disease to validate and expand upon previous findings, which demonstrated improvements in cognitive function, anxiety-related behavior, and sensory responsiveness. Through the remainder of fiscal 2026, InMed plans to further develop its Alzheimer's program, advancing Chemistry, Manufacturing, and Controls ("CMC") activities and preparing for a pre-IND meeting with the Food and Drug Administration ("FDA") and GLP-enabling studies to support an IND submission.
INM-089: Neuroprotection in the treatment of dry age-related macular degeneration ("AMD")
INM-089 is a proprietary small-molecule drug candidate under investigation for the treatment of dry AMD. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model.
Financial Commentary:
BayMedica commercial business generated revenues of $1.1 million for the three months ending September 30, 2025, compared to $1.3 million for the same period last year, reflecting an 11% decrease. This decrease is primarily attributed to pricing adjustments on BayMedica's products over the prior year. Cost of goods sold decreased by 7% for the three months ended September 30, 2025, as compared to the three months ended September 30, 2024. The decrease in cost of goods sold is primarily the result of the Company lowering its supply chain and manufacturing costs which has led to improved margins over time.
The Company's research and development expenses were $0.6 million for the three months ending September 30, 2025, compared with $0.7 million for the three months ending September 30, 2024. The decrease in research and development expenses was primarily due to reduced spending on external contractors and compensation. We expect research and development expenses to increase substantially through the remainder of fiscal year 2026 as the Company advances preclinical work and IND-enabling studies on INM-901.
The Company incurred general and administrative expenses of $1.5 million for the three months ended September 30, 2025 and 2024. We anticipate general and administrative expenses to remain relatively stable for the remainder of fiscal 2026.
As of September 30, 2025, the Company's cash and cash equivalents were $9.3 million, which compares to $11.1 million on June 30, 2025. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure into the fourth quarter of calendar year 2026, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses.
Table 1. Consolidated Balance Sheet
Expressed in U.S. Dollars
| September 30, | June 30, | ||||||
| 2025 | 2025 | ||||||
| (unaudited) | |||||||
| ASSETS | $ | $ | |||||
| Current | |||||||
| Cash and cash equivalents | 9,331,077 | 11,075,871 | |||||
| Short-term investments | 42,859 | 43,384 | |||||
| Accounts receivable, net | 343,469 | 465,104 | |||||
| Inventories, net | 890,807 | 961,173 | |||||
| Prepaids and other current assets | 191,755 | 321,747 | |||||
| Total current assets | 10,799,967 | 12,867,279 | |||||
| Â | Â | ||||||
| Non-Current | Â | Â | |||||
| Property, equipment and ROU assets, net | 881,549 | 992,199 | |||||
| Intangible assets, net | 1,579,569 | 1,620,562 | |||||
| Other assets | 100,000 | 100,000 | |||||
| Total Assets | 13,361,085 | 15,580,040 | |||||
| Â | Â | ||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | Â | Â | |||||
| Current | Â | Â | |||||
| Accounts payable and accrued liabilities | 1,130,219 | 1,404,283 | |||||
| Current portion of lease obligations | 424,765 | 435,507 | |||||
| Total current liabilities | 1,554,984 | 1,839,790 | |||||
| Â | Â | ||||||
| Non-current | Â | Â | |||||
| Lease obligations, net of current portion | 215,478 | 305,755 | |||||
| Total Liabilities | 1,770,462 | 2,145,545 | |||||
| Commitments and Contingencies (Note 10) | Â | Â | |||||
| Â | Â | ||||||
| Shareholders' Equity | Â | Â | |||||
| Common shares, no par value, unlimited authorized shares: 2,604,186 and 2,002,186 as of September 30, 2025 and June 30, 2025, respectively, issued and outstanding | 91,806,396 | 91,221,174 | |||||
| Additional paid-in capital | 38,620,449 | 39,322,644 | |||||
| Accumulated deficit | (118,964,791 | ) | (117,237,892 | ) | |||
| Accumulated other comprehensive income | 128,569 | 128,569 | |||||
| Total Shareholders' Equity | 11,590,623 | 13,434,495 | |||||
| Total Liabilities and Shareholders' Equity | 13,361,085 | 15,580,040 |
Â
Table 2. Consolidated Statements of Operations
Expressed in U.S. Dollars
| Â | Â | Â For the Three Months Ended | Â | |||||
| September 30, 2025 | September 30, 2024 | |||||||
| $ | $ | |||||||
| Sales | 1,120,121 | 1,264,638 | ||||||
| Cost of sales | 716,962 | 771,225 | ||||||
| Gross profit | 403,159 | 493,413 | ||||||
| Â | Â | |||||||
| Operating Expenses | Â | Â | ||||||
| Research and development | 581,612 | 700,145 | ||||||
| General and administrative | 1,532,015 | 1,492,961 | ||||||
| Amortization and depreciation | 53,202 | 54,579 | ||||||
| Foreign Exchange (Gain) Loss | 56,994 | (19,310 | ) | |||||
| Total operating expenses | 2,223,823 | 2,228,375 | ||||||
| Â | Â | |||||||
| Other Income (Expense) | Â | Â | ||||||
| Interest and other income | 93,765 | 57,094 | ||||||
| Loss before income tax expense | (1,726,899 | ) | (1,677,868 | ) | ||||
| Â | Â | |||||||
| Income tax expense | - | - | ||||||
| Net loss for the period | (1,726,899 | ) | (1,677,868 | ) | ||||
| Â | Â | |||||||
| Net loss per share for the period | Â | Â | ||||||
| Basic and diluted | (0.44 | ) | (2.71 | ) | ||||
| Weighted average outstanding common shares | Â | Â | ||||||
| Basic and diluted | 3,954,549 | 620,127 | ||||||
Â
Table 3. Consolidated Statements of Cash Flows
Expressed in U.S. Dollars
| For the Three Months Ended | |||||||
| September 30, 2025 | September 30, 2024 | ||||||
| Cash provided by (used in): | $ | $ | |||||
| Operating Activities | |||||||
| Net loss | (1,726,899 | ) | (1,677,868 | ) | |||
| Items not requiring cash: | Â | Â | |||||
| Amortization and depreciation | 53,202 | 54,579 | |||||
| Share-based compensation | 20,205 | 28,964 | |||||
| Amortization of right-of-use assets | 103,478 | 90,401 | |||||
| Unrealized foreign exchange loss | 1,358 | 5,270 | |||||
| Changes in operating assets and liabilities: | Â | Â | |||||
| Inventories | 70,366 | 24,251 | |||||
| Prepaids and other currents assets | 129,992 | 328,867 | |||||
| Accounts receivable | 122,160 | 67,624 | |||||
| Accounts payable and accrued liabilities | (274,066 | ) | (642,392 | ) | |||
| Payments on lease obligations | (107,412 | ) | (106,506 | ) | |||
| Total cash used in operating activities | (1,607,616 | ) | (1,826,810 | ) | |||
| Â | Â | ||||||
| Investing Activities | Â | Â | |||||
| Sale of short-term investments | 20,957 | 21,324 | |||||
| Purchase of short-term investments | (20,957 | ) | (21,324 | ) | |||
| Total cash used in investing activities | - | - | |||||
| Â | Â | ||||||
| Financing Activities | Â | Â | |||||
| Proceeds from the private placement | - | 1,030,063 | |||||
| Share issuance costs | (137,178 | ) | (191,824 | ) | |||
| Total cash provided by financing activities | (137,178 | ) | 838,239 | ||||
| Â | Â | ||||||
| Decrease in cash and cash equivalents during the period | (1,744,794 | ) | (988,571 | ) | |||
| Cash and cash equivalents beginning of the period | 11,075,871 | 6,571,610 | |||||
| Cash and cash equivalents end of the period | 9,331,077 | 5,583,039 | |||||
| Â | Â | ||||||
| SUPPLEMENTARY CASH FLOW INFORMATION: | Â | Â | |||||
| Cash paid during the period for: | Â | Â | |||||
| Income taxes | $ | - | - | ||||
| Interest | $ | - | $ | - | |||
| Â | - | ||||||
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | Â | Â | |||||
| Recognition of Right-of-use asset and corresponding operating lease | $ | - | $ | 187,223 | |||
Â
About InMed:
InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; data from its INM-901 program at the Alzheimer's Association International Conference (AAIC) 2025; statements regarding InMed's belief in the potential of INM-901 as a multi-mechanism small molecule drug candidate for Alzheimer's disease; fiscal 2026 is shaping up to be another strong year for InMed advancing INM-901 toward clinical readiness; entering an important stage in translating INM-901's scientific promise into clinical evaluation; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission; the further development, potential efficacy, and marketability of INM-089 for dry age-related macular degeneration; expectations regarding the sufficiency of the Company's strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273506
